Market Research Logo

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2015

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2015’, provides an overview of the Microscopic Polyangiitis (MPA)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Microscopic Polyangiitis (MPA) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Microscopic Polyangiitis (MPA) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Microscopic Polyangiitis (MPA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Microscopic Polyangiitis (MPA) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Microscopic Polyangiitis (MPA) Overview
Therapeutics Development
Pipeline Products for Microscopic Polyangiitis (MPA) – Overview
Pipeline Products for Microscopic Polyangiitis (MPA) – Comparative Analysis
Microscopic Polyangiitis (MPA) – Therapeutics under Development by Companies
Microscopic Polyangiitis (MPA) – Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Microscopic Polyangiitis (MPA) – Products under Development by Companies
Microscopic Polyangiitis (MPA) – Companies Involved in Therapeutics Development
Anthera Pharmaceuticals‚ Inc.
Aprogen, Inc.
ChemoCentryx, Inc.
Epirus Biopharmaceuticals, Inc.
Hospira, Inc.
Panacea Biotec Limited
Sandoz Inc.
Microscopic Polyangiitis (MPA) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
blisibimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCX-168 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Microscopic Polyangiitis (MPA) – Recent Pipeline Updates
Microscopic Polyangiitis (MPA) – Dormant Projects
Microscopic Polyangiitis (MPA) – Product Development Milestones
Featured News & Press Releases
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2015
Number of Products under Development for Microscopic Polyangiitis (MPA) – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Microscopic Polyangiitis (MPA) – Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015
Microscopic Polyangiitis (MPA) – Pipeline by Aprogen, Inc., H1 2015
Microscopic Polyangiitis (MPA) – Pipeline by ChemoCentryx, Inc., H1 2015
Microscopic Polyangiitis (MPA) – Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Microscopic Polyangiitis (MPA) – Pipeline by Hospira, Inc., H1 2015
Microscopic Polyangiitis (MPA) – Pipeline by Panacea Biotec Limited, H1 2015
Microscopic Polyangiitis (MPA) – Pipeline by Sandoz Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Microscopic Polyangiitis (MPA) Therapeutics – Recent Pipeline Updates, H1 2015
Microscopic Polyangiitis (MPA) – Dormant Projects, H1 2015
List of Figures
Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2015
Number of Products under Development for Microscopic Polyangiitis (MPA) – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report